For the Inventor, By the Inventor

Enter inventor name

Landenberg, PA, United States of America

James David Rodgers

USPTO Granted Patents = 86 (Patent Applications = 12)

CIPO Patents = 16 (Patent Applications = 1)

EPO Patents = 34 (Patent Applications = 32)

Average Co-Inventor Count = 3.0

ph-index = 39

Forward Citations = 3,807(Granted Patents)

Forward Citations (Not Self Cited) = 2,821(Dec 10, 2025)

Inventors with similar research interests:

Location History:

OveLandenberg, PA (US) (2013)
Bethany Beach, DE (US) (2018)
Landenberg, PA (US) (1996 - 2022)
Jupiter, FL (US) (2019 - 2023)

Company Filing History:

Incyte Corporation

Incyte Holdings Corporation

Bristol-myers Squibb Pharma Company

4. 5 out of 106

Dupont Pharmaceuticals Company

5. 4 out of 206

The Dupont Merck Pharmaceutical Company

6. 2 out of 3,684

Bristol-myers Squibb Compnay

Ineyte Corporation

Incyte Cororation

Dupont Pharmaceuticals, Inc.

Incyte Incorporation

11. 1 out of 16,338

E.i. Dupont De Nemours and Company

12. 1 out of 10

Bristol-myers Squibb Pharma Corporation

where one patent can have more than one assignee

Years Active: 1996-2023

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Janus Kinase Inhibitors

Tricyclic Heterocycles

BET Protein Inhibitors

Pyrrolo[2,3-b]Pyridines

Pyrrolo[2,3-b]Pyrimidines

Cyclobutyl Substituted Pyrrolopyridines

Cyclohexyl Azetidine Derivatives

Heteroaryl Substituted Compounds

Pyrazolyl-Substituted Pyrrolopyrimidines

Enantiomeric Excess Compounds

Heterocyclic Derivatives

Metabolites of JAK Inhibitors

86 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11744832 - Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors (2023-09-05),

2. 11498926 - Tricyclic heterocycles as BET protein inhibitors (2022-11-15),

3. 11331320 - Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors (2022-05-17),

4. 11213528 - Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (2022-01-04),

5. 11091484 - Tricyclic heterocycles as BET protein inhibitors (2021-08-17),

6. 10975085 - Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III (2021-04-13),

7. 10919912 - Tricyclic heterocycles as BET protein inhibitors (2021-02-16),

8. 10640506 - Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors (2020-05-05),

9. 10639310 - Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors (2020-05-05),

10. 10610530 - Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (2020-04-07),

11. 10464947 - Tricyclic heterocycles as BET protein inhibitors (2019-11-05),

12. 10463667 - Metabolites of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (2019-11-05),

13. 10442803 - Tricyclic heterocycles as bet protein inhibitors (2019-10-15),

14. 10398699 - Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors (2019-09-03),

15. 10364248 - Processes for preparing 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (2019-07-30),

Title: James David Rodgers - Pioneering Inventor from Landenberg

Introduction: James David Rodgers is a renowned inventor hailing from Landenberg, Pennsylvania. His innovative spirit and dedication to creating groundbreaking solutions have earned him a significant place in the world of patents and inventions.

Latest Patents: James David Rodgers holds several patents in various fields, including technology, healthcare, and environmental sustainability. His recent patents focus on enhancing renewable energy sources and improving medical devices for better patient outcomes.

Career Highlights: Throughout his illustrious career, James David Rodgers has been instrumental in developing cutting-edge technologies that have revolutionized industries. His contributions to the field of innovation have led to significant advancements in areas such as artificial intelligence and sustainable practices.

Collaborations: James David Rodgers has collaborated with leading research institutions, universities, and companies to bring his inventions to life. His partnerships have been crucial in bridging the gap between groundbreaking ideas and real-world applications.

Conclusion: James David Rodgers' passion for innovation and his relentless pursuit of excellence have cemented his legacy as a pioneering inventor. His work continues to inspire future generations to push the boundaries of what is possible through creativity and ingenuity.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…